July 22, 2020
First Patient Enrolled in Novocure’s EF-33 Phase 2 Pilot Trial of Tumor Treating Fields Delivered Utilizing High-Intensity Transducer Arrays
EF-33 will test the potential incremental survival benefit of Tumor Treating Fields delivered using high-intensity arrays in patients with recurrent glioblastoma ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today that the first patient has been enrolled in its EF-33 phase 2 pilot trial of Tumor Treating Fields delivered… Read More
learn more
July 15, 2020
Novocure Announces Clinical Trial Collaboration with MSD to Evaluate Tumor Treating Fields Together with KEYTRUDA® (pembrolizumab) in Non-Small Cell Lung Cancer
ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced it has entered into a clinical trial collaboration agreement with MSD (a tradename of Merck & Co., Inc.), through a subsidiary, to develop Tumor Treating Fields together with MSD’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) for treatment of non-small cell lung cancer (NSCLC). Read More
learn more
July 8, 2020
Novocure Announces Over 100 Physicians in the U.S. Now Certified to Prescribe Optune Lua™
Optune Lua, formerly known as NovoTTF-100L, was approved by the FDA one year ago and is the first FDA-approved treatment for malignant pleural mesothelioma in over 15 years ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced that over 100 physicians from more than 50 cancer treatment centers… Read More
learn more
July 7, 2020
Novocure Enrolls Last Patient in HEPANOVA Trial Testing Tumor Treating Fields in Combination with Sorafenib in Advanced Liver Cancer
Final data collection will occur in six months ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced that the last patient has been enrolled in the HEPANOVA trial, a phase 2 pilot trial testing Tumor Treating Fields in combination with sorafenib in patients with advanced liver cancer. The final… Read More
learn more
July 1, 2020
Novocure to Report Second Quarter 2020 Financial Results
ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today that it will report financial results for the second quarter 2020 on Thursday, July 30, 2020, before the U.S. financial markets open. Novocure’s management will host a conference call and webcast to discuss its financial results for the three and six… Read More
learn more
June 2, 2020
Novocure Announces Launch of MyLink™ to Enable Patient-Guided, Remote Download of Optune® Usage Data
ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced the launch of MyLink, a new tool that allows patients to download their Optune usage data from the comfort of home without the need for an in-person visit by a Novocure Device Support Specialist. Novocure initiated a phased launch with an… Read More
learn more
May 13, 2020
China NMPA Approves Optune® for the Treatment of Newly Diagnosed and Recurrent Glioblastoma
Optune is the first innovative treatment for glioblastoma approved in China in over 15 years A large, global phase 3 pivotal clinical study in newly diagnosed glioblastoma showed adding Optune to chemotherapy more than doubled the five-year overall survival rate1 ST. HELIER, Jersey & SHANGHAI–(BUSINESS… Read More
learn more
April 30, 2020
Novocure Reports First Quarter 2020 Financial Results and Provides Company Update
Quarterly net revenues of $101.8 million, representing 39 percent growth versus the first quarter 2019 and 3 percent growth versus the fourth quarter 2019 Balance sheet strength allows continued investments in innovation and the advancement of commercial and development priorities ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today… Read More
learn more
April 27, 2020
Novocure Announces Presentation of EF-19 Post-approval Registry Trial Data Studying Optune as a Monotherapy for the Treatment of Recurrent GBM at the American Association for Cancer Research 2020 Virtual Annual Meeting I
EF-19 data confirm the effectiveness and safety of Optune as monotherapy and further strengthen Optune’s clinical profile in recurrent GBM ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced that an abstract highlighting results from the EF-19 post-approval registry trial studying Optune for the treatment of recurrent GBM will… Read More
learn more
April 3, 2020
Novocure Provides Business Update Related to COVID-19
Novocure to report first quarter financial results on Thursday, April 30, 2020 ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today provided an update on its response to the global COVID-19 pandemic and an initial evaluation of the impact the pandemic may have on Novocure’s general business operations and clinical… Read More
learn more
